Novaferon inhalation (recombinant anti-tumor and anti-virus protein inhalation) / Genova - LARVOL DELTA

NOVATION-1: Phase 3 Inhaled Novaferon Study in Hospitalized Patients With Moderate to Severe COVID-19 (clinicaltrials.gov) - P3 | N=914 | Recruiting | Sponsor: Genova Inc. | Trial completion date: Aug 2021 ➔ Aug 2022 | Trial primary completion date: Aug 2021 ➔ Aug 2022

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Novaferon for COVID-19 Treatment Trial (NCTT-005) (clinicaltrials.gov) - P3 | N=385 | Recruiting | Sponsor: Genova Inc. | Not yet recruiting ➔ Recruiting | Trial completion date: Jun 2021 ➔ Apr 2023 | Trial primary completion date: May 2021 ➔ Apr 2023

Enrollment open • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Phase III Study of Novaferon in Non-hospitalized Adult Patients With Mild COVID-19 (clinicaltrials.gov) - P3; N=222; Recruiting; Sponsor: Genova Inc.

Clinical • New P3 trial • Infectious Disease • Novel Coronavirus Disease

A Trial of Novaferon in Asymptomatic or Mild COVID-19 Patients (clinicaltrials.gov) - P3; N=300; Not yet recruiting; Sponsor: Beijing 302 Hospital

Clinical • New P3 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

NOVATION-1: Phase 3 Inhaled Novaferon Study in Hospitalized Patients With Moderate to Severe COVID-19 (clinicaltrials.gov) - P3; N=914; Recruiting; Sponsor: Genova Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease

Clinical characteristics and drug therapies in patients with the common-type coronavirus disease 2019 in Hunan, China. (PubMed, Int J Clin Pharm) - "Pharmacotherapy included recombinant human interferon α2b, lopinavir/ritonavir, novaferon, antibiotics, systematic corticosteroids and traditional Chinese medicine prescription. Conclusion As of February 10, 2020, the symptoms of COVID-19 patients in Hunan province were relatively mild comparing to patients in Wuhan, the epicenter. We observed some treatment benefits with interferon-α2b and corticosteroid therapies but not with novaferon and antibiotic treatment in our study population."

Clinical • Journal • Fatigue • Immunology • Novel Coronavirus Disease

Reply to "Novaferon, Treatment in COVID-19 Patients". (PubMed, Int J Infect Dis) - No abstract available

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease

Clinical characteristics and drug therapies in patients with the common-type coronavirus disease 2019 in Hunan, China. (PubMed, Int J Clin Pharm) - "Pharmacotherapy included recombinant human interferon α2b, lopinavir/ritonavir, novaferon, antibiotics, systematic corticosteroids and traditional Chinese medicine prescription. Conclusion As of February 10, 2020, the symptoms of COVID-19 patients in Hunan province were relatively mild comparing to patients in Wuhan, the epicenter. We observed some treatment benefits with interferon-α2b and corticosteroid therapies but not with novaferon and antibiotic treatment in our study population."

Clinical • Journal • Retrospective data • Fatigue • Novel Coronavirus Disease

NOVATION-1: Phase 3 Inhaled Novaferon Study in Hospitalized Patients With Moderate to Severe COVID-19 (clinicaltrials.gov) - P3; N=914; Not yet recruiting; Sponsor: Genova Inc.; Initiation date: Jan 2021 ➔ Apr 2021

Clinical • Trial initiation date • Infectious Disease • Novel Coronavirus Disease

SARS-CoV-2 Clearance in COVID-19 Patients with Novaferon Treatment: A Randomized, Open-label, Parallel Group Trial. (PubMed, Int J Infect Dis) - "Novaferon exhibited anti-SARS-CoV-2 effects in vitro and in COVID-19 patients. These data justify further evaluation of Novaferon."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease

Comparative Effectiveness of Lopinavir/Ritonavir-Based Regimens in COVID-19. (PubMed, Clin Exp Pharmacol Physiol) - "The Coronavirus disease 2019 (COVID-19) is an epidemic disease caused by the Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) and spreading throughout the world rapidly. In conclusion, the combination of LPV/r and Novaferon may have better efficacy against COVID-19. However, adding IFN based on LPV/r+Novaferon or adding Arbidol based on LPV/r+IFN may not improve the efficacy."

HEOR • Journal • Infectious Disease • Novel Coronavirus Disease

Novaferon for COVID-19 Treatment Trial (NCTT-005) (clinicaltrials.gov) - P3; N=385; Not yet recruiting; Sponsor: Genova Inc.

Clinical • New P3 trial • Infectious Disease • Novel Coronavirus Disease

Novaferon, Treatment in COVID-19 Patients. (PubMed, Int J Infect Dis) - No abstract available

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease

Evaluation of Ganovo （Danoprevir ） Combined With Ritonavir in the Treatment of Novel Coronavirus Infection (clinicaltrials.gov) - P4; N=50; Recruiting; Sponsor: The Ninth Hospital of Nanchang

Clinical • New P4 trial • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

Recent Biotechnological Approaches for Treatment of Novel COVID-19: From Bench to Clinical Trial. (PubMed, Drug Metab Rev) - "To date, an effective drug for reliable treatment of COVID-19 has not been registered or introduced to the international community. This review aims to provide recently presented techniques and protocols for efficient treatment of COVID-19 and investigate its morphology and treatment/prevention approaches, among which usage of antiviral drugs, anti-malarial drugs, corticosteroids, and traditional medicines, biotechnological drugs (e.g., combination of HCQ and azithromycin, remdesivir, interferons, novaferon, interferon-alpha-1b, thymosin, and monoclonal antibodies) can be mentioned."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • IFNA1